CN113876677A - 一种石斛清润眼膜及其制备方法 - Google Patents
一种石斛清润眼膜及其制备方法 Download PDFInfo
- Publication number
- CN113876677A CN113876677A CN202111268256.7A CN202111268256A CN113876677A CN 113876677 A CN113876677 A CN 113876677A CN 202111268256 A CN202111268256 A CN 202111268256A CN 113876677 A CN113876677 A CN 113876677A
- Authority
- CN
- China
- Prior art keywords
- extract
- percent
- eye
- eye mask
- dendrobium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000004638 Dendrobium nobile Species 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 145
- 239000013543 active substance Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 19
- 230000004438 eyesight Effects 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000008367 deionised water Substances 0.000 claims abstract description 18
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 18
- 239000000758 substrate Substances 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 12
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 12
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 12
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 229940119170 jojoba wax Drugs 0.000 claims abstract description 12
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 9
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims description 28
- 240000008365 Celosia argentea Species 0.000 claims description 12
- 235000000722 Celosia argentea Nutrition 0.000 claims description 12
- 244000112814 pipewort Species 0.000 claims description 11
- 241001113925 Buddleja Species 0.000 claims description 10
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims description 9
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims description 9
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 claims description 9
- 239000001180 angelica archangelica l. root extract Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 claims description 8
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 7
- 241001071795 Gentiana Species 0.000 claims description 7
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 7
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- VMZJCIQOZYJFRB-UHFFFAOYSA-N 3-iodoprop-1-yn-1-ol Chemical compound OC#CCI VMZJCIQOZYJFRB-UHFFFAOYSA-N 0.000 claims description 6
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 6
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 6
- SKKTUOZKZKCGTB-UHFFFAOYSA-N butyl carbamate Chemical compound CCCCOC(N)=O SKKTUOZKZKCGTB-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- 241000565359 Fraxinus chinensis Species 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 241001523681 Dendrobium Species 0.000 claims description 3
- 241001135871 Gentiana scabra Species 0.000 claims description 3
- 241000972673 Phellodendron amurense Species 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 claims description 2
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 claims description 2
- 241000123846 Buddleja officinalis Species 0.000 claims description 2
- 229940064221 ligusticum wallichii root extract Drugs 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 35
- 208000002193 Pain Diseases 0.000 abstract description 7
- 208000003251 Pruritus Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 7
- 230000007803 itching Effects 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 230000006872 improvement Effects 0.000 abstract description 5
- 208000003464 asthenopia Diseases 0.000 abstract description 3
- 201000005111 ocular hyperemia Diseases 0.000 abstract description 3
- 235000002673 Dioscorea communis Nutrition 0.000 abstract description 2
- 241000544230 Dioscorea communis Species 0.000 abstract description 2
- 208000035753 Periorbital contusion Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241000007126 Codonopsis pilosula Species 0.000 description 5
- 241000475481 Nebula Species 0.000 description 5
- 238000005282 brightening Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102100029361 Aromatase Human genes 0.000 description 2
- 108010078554 Aromatase Proteins 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- 244000182022 Salvia sclarea Species 0.000 description 2
- 235000002911 Salvia sclarea Nutrition 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 244000201986 Cassia tora Species 0.000 description 1
- 235000014552 Cassia tora Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biomedical Technology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种石斛清润眼膜及其制备方法，该眼膜包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：舒目活性物5‑15％；明目活性物5‑10％；铁皮石斛提取物1‑5％；丁二醇1‑10％；海藻糖1‑5％；透明质酸0.1‑1％；氢化霍霍巴油0.1‑1％；胶原蛋白肽1‑5％；乙酰基六肽‑80.1‑1％；抗菌剂0.1‑0.5％；sp‑115c0.1‑1％；去离子水65‑75％。本发明优点为，在舒缓眼部疲劳、消除眼睛红肿涩、痒或痛方面有明显的增强效果，同时在改善包括黑眼圈在内的眼周皮肤的基础功效方面也有较好表现，同时能够有效修复眼角细纹和损伤并有效改善视力。
Description
技术领域
本发明涉及化妆品领域，具体涉及一种石斛清润眼膜及其制备方法。
背景技术
眼膜是用来敷眼的美容护肤品，是眼部肌肤问题的急救妙方和面膜有异曲同工之妙。眼膜是将具有吸附效果的眼膜基片(生物纤维膜、丝纤维、棉纤维、壳聚糖纤维、海藻纤维等制成的膜片材料)浸入眼膜液中充分吸附浸润。在使用时将吸附有眼膜液的眼膜基片敷于眼周，其能够在短时间内快速补充水份、消除疲劳并减低浮肿及黑眼圈。
现有技术中的常规眼膜通常专注于对黑眼圈、视疲劳等的缓解且功效一般，缺少一种能够增强基础皮肤护理功效的同时附加解决眼睛干涩以及红肿痒痛等常见眼部问题的综合性能优良的眼膜。
发明内容
本发明所要解决的技术问题是提供一种石斛清润眼膜及其制备方法，旨在克服现有技术中常规眼膜功能单一以及功效不足等缺点。
本发明解决上述技术问题的技术方案如下：一种石斛清润眼膜，其包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：舒目活性物5-15％；明目活性物5-10％；铁皮石斛提取物1-5％；丁二醇1-10％；海藻糖1-5％；透明质酸0.1-1％；氢化霍霍巴油0.1-1％；胶原蛋白肽1-5％；乙酰基六肽-80.1-1％；抗菌剂0.1-0.5％；sp-115c0.1-1％；去离子水65-75％。
在上述技术方案的基础上，本发明还可以做如下进一步的具体或最佳选择。
具体的，舒目活性物由占眼膜液如下百分含量的各原料组成：龙胆提取物0.5-5％；密蒙花提取物1-2％；谷精草提取物1-2％；青葙籽提取物1-2％；丹参根提取物0.5-1％；白蜡树提取物0.4-1％；田野薄荷提取物0.5-1％；薄荷烷甲酰乙胺0.1-1％。
具体的，明目活性物由占眼膜液如下百分含量的各原料组成：当归根提取物1-2％；党参提取物1-2％；川芎根提取物1-2％；防风根提取物0.5-1％；野菊花提取物0.5-1％；决明子提取物0.5-1％；黄皮树树皮提取物0.5-1％。
具体的，抗菌剂为苯氧乙醇和碘丙炔醇丁基氨甲酸酯中的任一种或两者任意比例混合。
具体的，眼膜液由以下百分含量的各原料组成：舒目活性物9％，分别为龙胆提取物3％、密蒙花提取物1％、谷精草提取物1％、青葙籽提取物1％、丹参根提取物1％、白蜡树提取物1％、田野薄荷提取物0.5％、薄荷烷甲酰乙胺0.5％；明目活性物6％，分别为当归根提取物1％、党参提取物1％、川芎根提取物0.5％、防风根提取物0.5％、野菊花提取物1％、决明子提取物1.3％、黄皮树树皮提取物0.7％；铁皮石斛提取物2％；丁二醇7.5％；海藻糖2％；透明质酸0.3％；氢化霍霍巴油0.2％；胶原蛋白肽2％；乙酰基六肽-80.5％；碘丙炔醇丁基氨甲酸酯0.2％；sp-115c0.3％；去离子水70％。
本发明还提供了制备上述的石斛清润眼膜的方法，其中眼膜液的制备包括如下步骤：按照相应的质量分数准备各原料，然后将丁二醇、海藻糖、透明质酸和氢化霍霍巴油依次投入相应量的去离子水中，升温至85-90℃，搅拌均匀，然后先加入sp-115c，再降温至50-60℃，随后于搅拌条件下依次加入相应量的胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物，搅拌均匀后，缓慢降温至25-30℃，加入抑菌剂，混匀后过滤，去除滤渣，即得。
在上述技术方案的基础上，具体的，当升温至85-90℃时，搅拌持续的时间为25-30min,搅拌转速为90-120r/min，降温至50-60℃后，加入相应量的胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物后搅拌持续时间为10-15min,搅拌转速为200-280r/min，搅匀后缓慢降温至25-30℃的降温速度为1-2℃/min，加入抵菌剂后，搅拌转速控制为50-80r/min，持续5-10min。
与现有技术相比，本发明的有益效果是：
(1)本发明采用的舒目活性物、明目活性物和铁皮石斛提取物适当比例配合在舒缓眼部疲劳、消除眼睛红肿涩、痒或痛方面有明显的增强效果，同时在改善眼周皮肤的基础功效方面也有较好表现；
(2)首次将龙胆提取物、密蒙花提取物、谷精草提取物、青葙籽提取物等植物提取成份与薄荷烷甲酰乙胺以特定比例合用作为舒目活性物，对眼睛赤红胀痛的改善有奇效，可带来更加明显舒适的清凉感且对眼睛无不适刺激；同时同为多种植物提取成分合用得到的明目活性物，能增强舒目效果且连续使用一段时间有较明显的明目效果。
(3)以胶原蛋白肽和乙酰基六肽-8配比使用，对于眼角细纹或开放性损伤具有较好的修复效果。
具体实施方式
以下结合具体实施例对本发明作进一步的详细描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
为免赘述，以下实施例中用到的药品若无特别说明则均为市售产品，用到的方法若无特别说明则均为本领域的常规方法。以下各实施例中用到的一些原料的基本情况和功效简述如下：
铁皮石斛提取物，为棕黄色精细粉末，提取方法为将原料用水抽提，浓缩萃取并干燥等步骤制成，以下实施例中使用西安优硕生物生产的10：1规格的产品，溶解度98％以上，粒度80-120目，核心活性成分系铁皮石斛多糖，具有活化巨噬细胞、抗氧化、增强免疫力等作用，在护肤方面主要有抗炎修复、止痒舒敏、抗辐射和抗衰老等功效，但使用方法多为内服。
密蒙花提取物，为流动性粉末，易溶于水，水分含量不超过5％，提取工艺包括原料→筛选→粉碎洗涤→投料→用水提取纯化→提取液→过滤→浓缩→浸膏→干燥→粉碎→过筛→混合等步骤，本申请中使用市售陕西杰恩生产的10：1规格的产品。其在化妆品、护肤品里主要作用是皮肤调理剂，风险系数为1，比较安全，可以放心使用，对于孕妇一般没有影响，密蒙花叶提取物没有致痘性。来源于密蒙花的叶部，其提取物中含有甘草酸等多种成分，具有清热利尿等功效，可用于日化产品中，能有效调理肌肤，改善皮肤健康状态。
谷精草提取物，味甘、辛、性平、归肝经，具有疏散风热,明目退翳之功效。谷精草中含有的黄酮类成分对引起众多眼部疾病的晶状体醛糖还原酶具有抑制作用，被广泛用来治疗眼部疾病提供了药理依据。
青葙籽提取物味苦,性微寒,归肝经，具有清肝火，祛风热的功效。主治肝热目赤肿痛，眼生翳膜，视物昏花，阳亢眩晕等，《本草纲目》：青葙子治眼，与决明子、苋实同功；《药性论》：治肝脏热毒冲眼，赤障、青盲、翳肿。现代研究发现，青葙子富含三萜皂苷类成分，对糖尿病视网膜病(DR)有很好的改善作用。
丹参提取物为棕红色的粉末，有特殊气味，不具引湿性；制备方法为，取丹参，粉碎成粗粉，加乙醇加热回流提取三次，滤过，合并滤液，减压回收乙醇并浓缩成相对密度为1.30-1.35(60℃)稠膏，用热水洗至洗液无色，80℃干燥，粉碎成细粉，即得。其具有扩张动物微动脉，改善微循环障碍的作用。
白蜡树提取物味苦，寒；归肝经、胆经、大肠经；有清热燥湿，清肝明目，收涩止痢，止带的功效；主治肝热目赤肿痛，目生翳障。《神农本草经》云：主风寒湿痹，洗洗寒气，除热，目中青翳白膜；《日华子本草》：洗肝，益精，明目，小儿热惊，皮肤风痹，退热。
田野薄荷叶提取物辛，凉，归肺，入肝经，功效包括:发散风热、清利头目，利咽，透疹，主要用于风热表证，头痛目赤，咽喉肿痛，麻疹不透，风疹瘙痒。
野菊花提取物的有效成份主要为菊花黄酮，产品成呈棕黄色粉末，本申请采用西安超邦生物生产的20:1规格的产品。其与常规野菊花提取液的功效相同，均有抗菌抗病毒、清热消炎、抗氧化预防皮肤衰老等作用，也用于风火赤眼、头痛眩晕等病症，具有收敛毛孔减少油脂的效果。
决明子提取物，以大黄素、大黄酚和决明素等为主要活性成分，生产时以干燥决明子为原料，经清洗、干燥、装罐，6立方米提取罐可装料1-1.5吨，10倍量70％乙醇-水，加热回流提取三次，每次2小时，合并提取液，回收乙醇至无醇，继续浓缩蒸发水至d＝1.15的浸膏，喷雾干燥塔进行喷雾干燥得决明子提取物粉，粉碎，过100目振动筛，混合，包装既得。
龙胆根提取物(龙胆提取物)，含龙胆苦甙3％左右，呈棕黄色精细粉末，制备过程中经过粉碎、提取、加热回流、提取物分离、浓缩和喷雾干燥等步骤。龙胆提取物在化妆品、护肤品里主要作用是气味抑制剂，皮肤调理剂，对荧光素酶的有很好的活化效果，说明对特异性皮炎和过敏有作用，可抑制刺激，起到抗炎的作用；对芳香化酶的活化，显示对皮肤局部的雌激素水平有作用，加之对弹性蛋白酶的抑制和抗氧性，具有抗衰老的作用；对表皮细胞胆甾醇的分泌有促进作用，胆甾醇是人体皮脂中一重要的柔润成分，可改善油性粗糙皮肤的状。
当归提取物，粉末，是一种用于补血活血，调经止痛，润肠通便，血虚萎黄，眩晕心悸，月经不调，经闭痛经，虚寒腹痛，肠燥便秘，风湿痹痛，跌扑损伤，痈疽疮疡的植物提取物。
党参提取物，从党参的根部提取的，纯天然萃取产物，含有甾醇、党参苷和生物碱等组分，可补中益气，健脾益肺，适用于气血两亏的病症，可达到调理皮肤的效果。
川芎提取物，抑制自由基的生成，有效清除氧自由基；在较低浓度下，可有效抑制黑色素细胞的活性，减少黑色素的生成，但浓度过高则显示其细胞毒性作用；同时具有吸湿性，具有保湿作用。
防风根提取物，对多种自由基有消除作用，可用作抗氧化剂；对黑色素有一定的抑制作用，可用作美白产品；可以收缩毛孔，用作收敛剂；同时具有抗菌消炎的作用。
黄皮树树皮提取物，含小檗碱，能促进胶原蛋白的生成，结合其抗氧化性，有抗衰的作用；能抑制毛发的生长，结合对芳香化酶的活化作用，可用于皮肤多毛症；同时具有抗炎性和抑臭的作用。
以下实施例或对比例(缺省某原料时对应不添加)中的眼膜液通过如下方法进行制备，包括如下步骤：
按照相应的质量分数准备各原料，然后将丁二醇、海藻糖、透明质酸和氢化霍霍巴油依次投入相应量的去离子水中，升温至85℃，搅拌均匀，然后先加入sp-115c，再降温至60℃，随后于搅拌条件下依次加入相应量的胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物，搅拌均匀后，缓慢降温至25℃，加入抑菌剂，混匀后过滤，去除滤渣，即得。上述指备过程中，当升温至85℃时，搅拌持续的时间为25min,搅拌转速为110r/min，降温至60℃后，加入胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物后搅拌持续时间为15min,搅拌转速为240r/min，搅匀后缓慢降温至25℃的降温速度为1℃/min，加入抵菌剂后，搅拌转速控制为80r/min，持续10min。
实施例1
一种石斛清润眼膜，其包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：
舒目活性物9％，分别为龙胆提取物3％、密蒙花提取物1％、谷精草提取物1％、青葙籽提取物1％、丹参根提取物1％、白蜡树提取物1％、田野薄荷提取物0.5％、薄荷烷甲酰乙胺0.5％；明目活性物6％，分别为当归根提取物1％、党参提取物1％、川芎根提取物0.5％、防风根提取物0.5％、野菊花提取物1％、决明子提取物1.3％、黄皮树树皮提取物0.7％；铁皮石斛提取物2％；丁二醇7.5％；海藻糖2％；透明质酸0.3％；氢化霍霍巴油0.2％；胶原蛋白肽2％；乙酰基六肽-80.5％；碘丙炔醇丁基氨甲酸酯0.2％；sp-115c0.3％；去离子水70％。
实施例2
一种石斛清润眼膜，其包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：
舒目活性物5％，分别为龙胆提取物0.5％、密蒙花提取物1％、谷精草提取物1％、青葙籽提取物1％、丹参根提取物0.5％、白蜡树提取物0.4％、田野薄荷提取物0.5％、薄荷烷甲酰乙胺0.1％；明目活性物10％，分别为当归根提取物2％、党参提取物2％、川芎根提取物2％、防风根提取物1％、野菊花提取物1％、决明子提取物1％、黄皮树树皮提取物1％；铁皮石斛提取物5％；丁二醇3％；海藻糖2.5％；透明质酸1％；氢化霍霍巴油1％；胶原蛋白肽5％；乙酰基六肽-81％；碘丙炔醇丁基氨甲酸酯0.5％；sp-115c1％；去离子水65％。
实施例3
一种石斛清润眼膜，其包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：
舒目活性物10％，分别为龙胆提取物4％、密蒙花提取物1％、谷精草提取物1％、青葙籽提取物1％、丹参根提取物1％、白蜡树提取物1％、田野薄荷提取物0.5％、薄荷烷甲酰乙胺0.5％；明目活性物5％，分别为当归根提取物1％、党参提取物1％、川芎根提取物1％、防风根提取物0.5％、野菊花提取物0.5％、决明子提取物0.5％、黄皮树树皮提取物0.5％；铁皮石斛提取物1％；丁二醇10％；海藻糖1％；透明质酸0.5％；氢化霍霍巴油0.1％；胶原蛋白肽1％；乙酰基六肽-80.8％；碘丙炔醇丁基氨甲酸酯0.5％；sp-115c0.1％；去离子水70％。
实施例4
一种石斛清润眼膜，其包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：
舒目活性物15％，分别为龙胆提取物5％、密蒙花提取物2％、谷精草提取物2％、青葙籽提取物2％、丹参根提取物1％、白蜡树提取物1％、田野薄荷提取物1％、薄荷烷甲酰乙胺1％；明目活性物5％，分别为当归根提取物1％、党参提取物1％、川芎根提取物0.5％、防风根提取物0.5％、野菊花提取物1％、决明子提取物1.3％、黄皮树树皮提取物0.7％；铁皮石斛提取物1％；丁二醇1％；海藻糖1％；透明质酸0.3％；氢化霍霍巴油0.1％；胶原蛋白肽1％；乙酰基六肽-80.2％；碘丙炔醇丁基氨甲酸酯0.2％；sp-115c0.2％；去离子水75％。
对比例1
与实施例1相比，对比例1对应的清润眼膜的眼膜液不含有铁皮石斛提取物，微调去离子水含量(调整后含水量约71％)，其余保持不变。
对比例2
与实施例1相比，对比例2对应的清润眼膜的眼膜液不含有舒目活性物，微调去离子水含量(调整后含水量约68％)，其余保持不变。
对比例3
与实施例1相比，对比例3对应的清润眼膜的眼膜液不含有明目活性物，微调去离子水含量(调整后含水量约70％)，其余保持不变。
对比例4
与实施例1相比，对比例4对应的清润眼膜的眼膜液不含有胶原蛋白肽，微调去离子水含量(调整后含水量约70％)，其余保持不变。
对比例5
与实施例1相比，对比例5对应的清润眼膜的眼膜液不含有酰基六肽-8，微调去离子水含量(调整后含水量约71％)，其余保持不变。
对比例6
与实施例1相比，对比例6对应的清润眼膜的眼膜液不含有酰基六肽-8，且将胶原蛋白肽的含量调整至4％，微调去离子水含量(调整后含水量约70％)，其余保持不变。
对比例7
以市售销量排名靠前的伊诗兰顿抹茶紧致眼贴膜产品为本对比例产品。
石斛清润眼膜使用效果验证：
选择有黑眼圈(后天产生)、眼角细纹或眼干痒涩痛等问题的健康成年女性为试用对象，以年龄25-50岁的上班族为主，根据症状问题不同分成多个组，每个组20人(个别受试者可能有两种或多种症状，故可交叉存在于不同组中)。验证方法如下：将受试人员分成多组，每间隔4天使用一次对应实施例或对比例的眼膜贴，坚持使用一个月后观察结果，结果如下表所示：
分析上表结果可知，本发明提供的石斛清润眼膜不仅具有与现有常规眼膜产品相当甚至更好的消减黑眼圈的效果，同时在针对眼干痒涩红肿痛、眼角细纹及改善视力(明目)等方面均有优异表现，明显优于市售常规产品。同时舒目活性物、明目活性物及石斛提取物对于上述各方面功效的产生有明显的协同效果，胶原蛋白肽和酰基六肽-8在消除眼角细纹方面有明显的配合增加作用。
以上仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (7)
1.一种石斛清润眼膜，其特征在于，包括眼膜基片及用于浸润眼膜基片的眼膜液，眼膜液由以下质量百分数的各原料组成：舒目活性物5-15％；明目活性物5-10％；铁皮石斛提取物1-5％；丁二醇1-10％；海藻糖1-5％；透明质酸0.1-1％；氢化霍霍巴油0.1-1％；胶原蛋白肽1-5％；乙酰基六肽-80.1-1％；抗菌剂0.1-0.5％；sp-115c 0.1-1％；去离子水65-75％。
2.根据权利要求1的一种石斛清润眼膜，其特征在于，舒目活性物由占眼膜液如下百分含量的各原料组成：龙胆提取物0.5-5％；密蒙花提取物1-2％；谷精草提取物1-2％；青葙籽提取物1-2％；丹参根提取物0.5-1％；白蜡树提取物0.4-1％；田野薄荷提取物0.5-1％；薄荷烷甲酰乙胺0.1-1％。
3.根据权利要求1的一种石斛清润眼膜，其特征在于，明目活性物由占眼膜液如下百分含量的各原料组成：当归根提取物1-2％；党参提取物1-2％；川芎根提取物0.5-1％；防风根提取物0.5-1％；野菊花提取物1-2％；决明子提取物0.5-1％；黄皮树树皮提取物0.5-1％。
4.根据权利要求1的一种石斛清润眼膜，其特征在于，抗菌剂为苯氧乙醇和碘丙炔醇丁基氨甲酸酯中的任一种或两者任意比例混合。
5.根据权利要求1至5任一项的一种石斛清润眼膜，其特征在于，眼膜液由以下百分含量的各原料组成：舒目活性物9％，分别为龙胆提取物3％、密蒙花提取物1％、谷精草提取物1％、青葙籽提取物1％、丹参根提取物1％、白蜡树提取物1％、田野薄荷提取物0.5％、薄荷烷甲酰乙胺0.5％；明目活性物6％，分别为当归根提取物1％、党参提取物1％、川芎根提取物0.5％、防风根提取物0.5％、野菊花提取物1％、决明子提取物1.3％、黄皮树树皮提取物0.7％；铁皮石斛提取物2％；丁二醇7.5％；海藻糖2％；透明质酸0.3％；氢化霍霍巴油0.2％；胶原蛋白肽2％；乙酰基六肽-8 0.5％；碘丙炔醇丁基氨甲酸酯0.2％；sp-115c0.3％；去离子水70％。
6.一种制备如权利要求1至5任一项的石斛清润眼膜的方法，其特征在于，眼膜液的制备包括如下步骤：按照相应的质量分数准备各原料，然后将丁二醇、海藻糖、透明质酸和氢化霍霍巴油依次投入相应量的去离子水中，升温至85-90℃，搅拌均匀，然后先加入sp-115c，再降温至50-60℃，随后于搅拌条件下依次加入相应量的胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物，搅拌均匀后，缓慢降温至25-30℃，加入抑菌剂，混匀后过滤，去除滤渣，即得。
7.根据权利要求6的石斛清润眼膜的方法，其特征在于，当升温至85-90℃时，搅拌持续的时间为25-30min,搅拌转速为90-120r/min，降温至50-60℃后，加入相应量的胶原蛋白肽、乙酰基六肽-8、舒目活性物、明目活性物和铁皮石斛提取物后搅拌持续时间为10-15min,搅拌转速为200-280r/min，搅匀后缓慢降温至25-30℃的降温速度为1-2℃/min，加入抵菌剂后，搅拌转速控制为50-80r/min，持续5-10min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111268256.7A CN113876677A (zh) | 2021-10-29 | 2021-10-29 | 一种石斛清润眼膜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111268256.7A CN113876677A (zh) | 2021-10-29 | 2021-10-29 | 一种石斛清润眼膜及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113876677A true CN113876677A (zh) | 2022-01-04 |
Family
ID=79014253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111268256.7A Pending CN113876677A (zh) | 2021-10-29 | 2021-10-29 | 一种石斛清润眼膜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113876677A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160000858A1 (en) * | 2014-07-07 | 2016-01-07 | Gojo Industries, Inc. | Compositions and methods for mitigating skin irritation and enhancing skin barrier function |
| BE1025922A1 (fr) * | 2017-11-21 | 2019-08-08 | Shanghai Lofty Brand Man Co Ltd | Crème contour des yeux anti-rides et procédé de préparation de celle-ci |
| CN111728882A (zh) * | 2020-07-27 | 2020-10-02 | 长沙蓝姿生物科技有限公司 | 一种长效修护眼膜 |
| CN113133957A (zh) * | 2021-04-25 | 2021-07-20 | 广东舒畅日用品有限公司 | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 |
-
2021
- 2021-10-29 CN CN202111268256.7A patent/CN113876677A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160000858A1 (en) * | 2014-07-07 | 2016-01-07 | Gojo Industries, Inc. | Compositions and methods for mitigating skin irritation and enhancing skin barrier function |
| BE1025922A1 (fr) * | 2017-11-21 | 2019-08-08 | Shanghai Lofty Brand Man Co Ltd | Crème contour des yeux anti-rides et procédé de préparation de celle-ci |
| CN111728882A (zh) * | 2020-07-27 | 2020-10-02 | 长沙蓝姿生物科技有限公司 | 一种长效修护眼膜 |
| CN113133957A (zh) * | 2021-04-25 | 2021-07-20 | 广东舒畅日用品有限公司 | 一种植物发酵提拉紧致抗氧化抗疲劳眼贴膜及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 广州婷薇生物科技有限公司: "VIMETIME微美时代黄金肽水光眼膜", 《国产非特殊用途化妆品备案服务平台》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102631306A (zh) | 一种含中药成份的祛斑美白面膜 | |
| CN104338083A (zh) | 一种治疗月经不调的药物及其制备方法 | |
| CN104383296B (zh) | 一种用于治疗干眼症的中药组合物及其制备方法 | |
| CN105496917A (zh) | 一种积雪草抗皱面霜及其制备方法 | |
| CN110624089A (zh) | 一种可生发育发的外用中药组合物及其制备方法 | |
| CN109646518A (zh) | 杜仲眼贴及其制备方法 | |
| CN111617197A (zh) | 一种生发养发的中药组合物及其制备方法与应用 | |
| CN113730479A (zh) | 一种具有保健功能的组合物及其制备方法与用途 | |
| CN104547584A (zh) | 一种促进刨宫产手术后切口愈合的中药喷剂及制备方法 | |
| CN110693797A (zh) | 一种明眸精华液 | |
| CN114010571B (zh) | 一种安肤、改善肤质的天然提取物及其应用 | |
| CN105194487A (zh) | 一种美白养颜中药组合物及其面膜和制备方法 | |
| CN105748374A (zh) | 中药嫩肤养颜美容液 | |
| CN104940886A (zh) | 一种治疗脂溢性脱发的外用制剂及制法 | |
| CN113876677A (zh) | 一种石斛清润眼膜及其制备方法 | |
| CN115006336A (zh) | 一种防脱健发、去屑止痒植物洗发水及其制备方法 | |
| CN107961323A (zh) | 一种痤疮药膏及其制备方法 | |
| CN106729100A (zh) | 具有消炎、美容的外用中药保健制剂及其制备方法 | |
| CN103735959B (zh) | 一种治疗瘢痕的中药组合物及其制备方法 | |
| CN105687051A (zh) | 具有除粉刺效果的沐浴盐及制备方法 | |
| CN112138096A (zh) | 用于头皮保健黑发生发的药物组合物及其制备方法与用途 | |
| CN105920379A (zh) | 一种缓解眼袋的中药眼霜及其制备方法 | |
| CN110638730A (zh) | 一种润养精华液及其制备方法 | |
| CN116459314B (zh) | 一种延缓衰老喷剂 | |
| CN109045186B (zh) | 一种消痔散及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220104 |